BG
PCVX icon

Bellevue Group’s Vaxcyte PCVX Stock Holding History

Bellevue Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115M Buy
1,971,935
+781,238
+66% +$42.4M 2.41% 12
2026
Q1 		$69.2M Buy
+1,190,697
New +$64.6M 1.65% 22
2025
Q2 		– Sell
-11,290
Closed -$426K – 149
2025
Q1 		$426K Sell
11,290
-748
-6% -$59.8K 0.01% 121
2024
Q4 		$985K Buy
12,038
+57
+0.5% +$5.66K 0.02% 115
2024
Q3 		$1.37M Sell
11,981
-2,229
-16% -$201K 0.02% 112
2024
Q2 		$1.07M Buy
14,210
+966
+7% +$65.8K 0.02% 121
2024
Q1 		$905K Sell
13,244
-2,556
-16% -$177K 0.01% 123
2023
Q4 		$992K Sell
15,800
-14,700
-48% -$763K 0.02% 123
2023
Q3 		$1.55M Buy
30,500
+4,500
+17% +$222K 0.03% 116
2023
Q2 		$1.3M Buy
+26,000
New +$1.23M 0.02% 121

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Bellevue Group's PCVX Position: Q2 2026 in Review

Bellevue Group increased its Vaxcyte (PCVX) stake by 66% in Q2 2026, buying an estimated $42.4M and bringing the position to 1,971,935 shares worth $115M. The position accounts for 2.41% of the portfolio, ranked #12.

Bellevue Group first reported a position in PCVX in Q2 2023 and has held it in 10 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Bellevue Group held 1,971,935 shares of Vaxcyte worth $115M as of Q2 2026.
  • Bellevue Group bought 781,238 Vaxcyte shares in Q2 2026, an estimated $42.4M.
  • Vaxcyte made up 2.41% of Bellevue Group's portfolio in Q2 2026, its #12 holding.
  • Bellevue Group first reported a position in Vaxcyte in Q2 2023 and has held it in 10 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.